IXICO Financial Statements From 2010 to 2025
| PHYOF Stock | USD 0.07 0.00 0.00% |
Check IXICO Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IXICO Plc's main balance sheet or income statement drivers, such as , as well as many indicators such as . IXICO financial statements analysis is a perfect complement when working with IXICO Plc Valuation or Volatility modules.
IXICO |
IXICO plc Company Return On Equity Analysis
IXICO Plc's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current IXICO Plc Return On Equity | 0.0861 |
Most of IXICO Plc's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IXICO plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, IXICO plc has a Return On Equity of 0.0861. This is 100.36% lower than that of the Healthcare sector and 100.24% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 127.77% lower than that of the firm.
IXICO plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IXICO Plc's current stock value. Our valuation model uses many indicators to compare IXICO Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IXICO Plc competition to find correlations between indicators driving IXICO Plc's intrinsic value. More Info.IXICO plc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.46 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for IXICO plc is roughly 2.19 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IXICO Plc's earnings, one of the primary drivers of an investment's value.About IXICO Plc Financial Statements
IXICO Plc stakeholders use historical fundamental indicators, such as IXICO Plc's revenue or net income, to determine how well the company is positioned to perform in the future. Although IXICO Plc investors may analyze each financial statement separately, they are all interrelated. For example, changes in IXICO Plc's assets and liabilities are reflected in the revenues and expenses on IXICO Plc's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in IXICO plc. Please read more on our technical analysis and fundamental analysis pages.
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom. IXICO PLC operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 93 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in IXICO Pink Sheet
IXICO Plc financial ratios help investors to determine whether IXICO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IXICO with respect to the benefits of owning IXICO Plc security.